APA (7th ed.) Citation

M, S., I, Z., JM, S., R, A., N, L., M, C., . . . J, M. (2026). Impact of 1q vulnerabilities in patients treated with anti-CD38 monoclonal antibodies. Frontiers in oncology, 16, 1758533. https://doi.org/10.3389/fonc.2026.1758533

Chicago Style (17th ed.) Citation

M, Sánchez-Tabernero, et al. "Impact of 1q Vulnerabilities in Patients Treated with Anti-CD38 Monoclonal Antibodies." Frontiers in Oncology 16 (2026): 1758533. https://doi.org/10.3389/fonc.2026.1758533.

MLA (9th ed.) Citation

M, Sánchez-Tabernero, et al. "Impact of 1q Vulnerabilities in Patients Treated with Anti-CD38 Monoclonal Antibodies." Frontiers in Oncology, vol. 16, 2026, p. 1758533, https://doi.org/10.3389/fonc.2026.1758533.